Glikokortykosteroidy wziewne i długo działający β2-agoniści w leczeniu astmy i POChP. Znaczenie propionianu flutykazonu i salmeterolu w utrzymaniu kontroli astmy i POChP Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2017
Słowa kluczowe:
astma, przewlekła obturacyjna choroba płuc, glikokortykosteroidy wziewne, długo działający β2-agonista, propionian flutykazonu, salmeterol
##plugins.themes.bootstrap3.article.main##
Abstrakt
Wziewne glikokortykosteroidy w połączeniu z długo działającymi β2-agonistami pozostają ważną opcją terapeutyczną w chorobach obturacyjnych płuc. Omówiono działanie leków oraz wskazania do ich stosowania w leczeniu astmy i POChP.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Obojski, A. (2017). Glikokortykosteroidy wziewne i długo działający β2-agoniści w leczeniu astmy i POChP. Znaczenie propionianu flutykazonu i salmeterolu w utrzymaniu kontroli astmy i POChP. Medycyna Faktów , 10(4(37), 302-305. https://doi.org/10.24292/01.MF.0417.1
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Barnes P.J.: Molecular mechanisms of steroid action in asthma. J. Allergy Clin. Immunol. 1996; 97: 159.
2. Greening A.P., Ind P.W., Northfield M., Shaw G.: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994, 344: 219-224.
3. Wenzel S.E.: Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012; 18: 716-725.
4. Brusselle G., Bracke K.: Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 2014; 11: S322-328.
5. Demoly P., Annunziata K., Gubba E., Adamek L.: Repeated cross-sectional survey of patientreported asthma control in Europe in the past 5 years. Eur. Respir. Rev. 2012; 21: 66-74.
6. Price D., Fletcher M., van der Molen T.: Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. Primary Care Resp. Med. 2014: 24: 14009.
7. World Health Organization. The top 10 causes of death [online].
8. GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD [online].
9. Pascoe S., Locantore N., Dransfield M.T. et al.: Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3: 435-442.
10. Siddiqui S.H., Guasconi A., Vestbo J. et al.: Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2015; 192: 523-525.
11. Agusti A., Hurd S., Jones P. et al.: FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur. Respir. J. 2013; 42: 1391-1401.
12. Calverley P.M.A., Anderson J.A., Celli B. et al.: Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 2007; 356: 775-789.
13. European Medicines Agency. PRAC reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease. EMA/197713/2016; 18 March 2016.
14. Gibson P.G., McDonald V.M.: Asthma-COPD overlap 2015: now we are six. Thorax 2015; 70: 683-691.
2. Greening A.P., Ind P.W., Northfield M., Shaw G.: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994, 344: 219-224.
3. Wenzel S.E.: Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012; 18: 716-725.
4. Brusselle G., Bracke K.: Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 2014; 11: S322-328.
5. Demoly P., Annunziata K., Gubba E., Adamek L.: Repeated cross-sectional survey of patientreported asthma control in Europe in the past 5 years. Eur. Respir. Rev. 2012; 21: 66-74.
6. Price D., Fletcher M., van der Molen T.: Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. Primary Care Resp. Med. 2014: 24: 14009.
7. World Health Organization. The top 10 causes of death [online].
8. GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD [online].
9. Pascoe S., Locantore N., Dransfield M.T. et al.: Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3: 435-442.
10. Siddiqui S.H., Guasconi A., Vestbo J. et al.: Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2015; 192: 523-525.
11. Agusti A., Hurd S., Jones P. et al.: FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur. Respir. J. 2013; 42: 1391-1401.
12. Calverley P.M.A., Anderson J.A., Celli B. et al.: Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 2007; 356: 775-789.
13. European Medicines Agency. PRAC reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease. EMA/197713/2016; 18 March 2016.
14. Gibson P.G., McDonald V.M.: Asthma-COPD overlap 2015: now we are six. Thorax 2015; 70: 683-691.